Skip to main content

Table 1 Baseline characteristics of patients with different types of atrial fibrillation

From: Impact of estimated glomerular filtration rate on long-term clinical outcomes among Chinese patients with atrial fibrillation

  Total population
n = 433
Individuals with VHDs Individuals without VHDs
n = 283
P value
ERHA Type 1
n = 91
ERHA Type 2
n = 59
Male, n (%) 221 (51.0) 29 (31.9) 30 (50.8) 162 (57.2)  < 0.001
Age, years (SD) 65.6 (13.2) 58.0 (11.1) 62.9 (16.0) 65.5 (12.7)  < 0.001
BMI, kg/m2(SD) 24.2 (3.8) 22.8 (3.4) 22.8 (3.6) 24.8 (3.7)  < 0.001
SBP, mmHg (SD) 122.8 (22.3) 117.3 (20.3) 123.2 (23.5) 124.5 (22.4) 0.025
Heart rate, beats/min (SD) 102.5 (29.9) 100.5 (29.4) 97.9 (29.0) 104.1 (30.2) 0.273
Duration of AF       < 0.001
 Paroxysmal, n (%) 79 (18.2) 11 (12.1) 15 (25.4) 53 (18.7)  
 Persistent, n (%) 177 (40.9) 21 (23.1) 6 (10.2) 150 (53.0)  
 Permanent, n (%) 177 (40.9) 59 (64.8) 38 (64.4) 80 (28.3)  
Smoking, n (%) 112 (25.9) 12 (13.2) 16 (27.1) 84 (29.7) 0.007
Alcohol, n (%) 36 (8.3) 4 (4.4) 6 (10.2) 26 (9.2) 0.304
Hypertension, n (%) 224 (51.7) 23 (25.3) 31 (52.5) 170 (60.1)  < 0.001
Diabetes, n (%) 171 (39.5) 31 (34.1) 28 (47.5) 112 (39.6) 0.261
Hypercholesterolemia, n (%) 22 (5.1) 0 (0) 7 (11.9) 15 (5.3) 0.005
TIA or Stroke, n (%) 61 (14.1) 11 (12.1) 7 (11.9) 43 (15.2) 0.661
CADs, n (%) 107 (24.7) 5 (5.5) 11 (18.6) 91 (32.2)  < 0.001
Heart failure, n (%) 243 (56.3) 74 (81.3) 51 (86.4) 118 (41.7)  < 0.001
CHA2DS2-VASc Score      
 Mean (SD) 3.4 (1.6) 3.1 (1.8)
 Median (IQR) 3 (2–4) 3 (2–4)
  ≥ 2(Male) or ≥ 3(female), n (%) 49 (83.1) 211 (74.6)
ALT, u/l (IQR) 19 (14.0–31.3) 18 (14–27) 23 (15–40) 19 (14–32) 0.223
eGFR, ml/(min·1.73 m2) 70.1 (26.9) 73.2 (25.1) 64.9 (27.1) 70.1 (27.4) 0.197
eGFR < 60 ml/(min·1.73 m2), n (%) 154 (35.6) 28 (30.8) 28 (47.5) 98 (34.6) 0.309
Warfarin, n (%) 119 (27.5) 55 (60.4) 23 (39.0) 41 (14.5)  < 0.001
INR, mean (SD)a 1.91 (0.77) 2.16 (0.76) 1.83 (0.75) 1.51 (0.62)  < 0.001
TiTR ≥ 66%, n (%)a 27 (22.7) 21 (38.2) 5 (21.7) 2 (4.9)  < 0.001
Antiplatelet agents, n (%) 214 (49.4) 25 (27.5) 23 (39.0) 166 (58.7)  < 0.001
Beta blockers, n (%) 266 (61.4) 48 (52.7) 38 (64.4) 180 (63.6) 0.159
ACEIs/ARBs, n (%) 146 (33.7) 19 (20.9) 22 (37.3) 105 (37.1) 0.014
CCBs, n (%) 87 (20.1) 6 (6.6) 11 (18.6) 70 (24.7) 0.001
  1. VHD indicates valvular heart diseases
  2. CHA2DS2-VASc score was calculated by congestive heart failure, hypertension, age ≥ 75 years (doubled), diabetes mellitus, prior stroke or TIA (doubled), vascular disease, age 65 to74 years and female sex
  3. BMI body mass index, SBP systolic blood pressure, AF atrial fibrillation, TIA transient ischemic attack, CADs coronary artery diseases, IQR interquartile range, eGFR stimated Glomerular filtration rate, ALT alanine aminotransferase, INR international normalized ratio, TiTR time in therapeutic range, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, CCB calcium channel blocker
  4. aOnly patients treated with warfarin were included